Dr. Luca Szalontay, MD
Claim this profileNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Expert in Tumors
Expert in Brain Tumor
20 reported clinical trials
28 drugs studied
About Luca Szalontay, MD
Education:
- Earned an MD from Columbia University Vagelos College of Physicians and Surgeons in 2017.
- Completed a Residency in Internal Medicine at NewYork-Presbyterian/Columbia University Medical Center in 2021.
- Undertook a Fellowship in Hematology and Oncology at Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian/Columbia University Medical Center, expected completion in 2024.
Experience:
- Specialized training in Internal Medicine, Hematology, and Oncology at NewYork-Presbyterian/Columbia University Medical Center.
Area of expertise
1Tumors
Global LeaderStage IV
NTRK1 positive
NTRK positive
2Brain Tumor
Global LeaderH3 K27M positive
NTRK1 positive
NTRK positive
Affiliated Hospitals
Clinical Trials Luca Szalontay, MD is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting1 award Phase 1 & 213 criteria
More about Luca Szalontay, MD
Clinical Trial Related7 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Luca Szalontay, MD has experience with
- Larotrectinib
- Tipifarnib
- Selpercatinib
- ONC201
- MTX110
- Convection-Enhanced Delivery (CED)
Breakdown of trials Luca Szalontay, MD has run
Tumors
Brain Tumor
Recurrence
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Luca Szalontay, MD specialize in?
Luca Szalontay, MD focuses on Tumors and Brain Tumor. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are NTRK1 positive.
Is Luca Szalontay, MD currently recruiting for clinical trials?
Yes, Luca Szalontay, MD is currently recruiting for 8 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Luca Szalontay, MD has studied deeply?
Yes, Luca Szalontay, MD has studied treatments such as Larotrectinib, Tipifarnib, Selpercatinib.
What is the best way to schedule an appointment with Luca Szalontay, MD?
Apply for one of the trials that Luca Szalontay, MD is conducting.
What is the office address of Luca Szalontay, MD?
The office of Luca Szalontay, MD is located at: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York 10032 United States. This is the address for their practice at the NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.